Ctrl Worx Watch List › Company

Climb Bio, Inc. (CLYM): material weakness open 1,947 days

By , Ctrl Worx™. Built from its own SEC filings. How the Clock works.

Climb Bio, Inc. reported ineffective internal control over financial reporting because of a material weakness in 4 filings since Mar 6, 2023. It stated one or more material weaknesses in 17 more SEC filings that gave no conclusion on whether that control is effective. The latest was its 10-Q for the period ended Jun 30, 2026.

Ctrl Worx Watch List™ status

On the Clock
5.3 yearsopen since Jun 30, 2021
10-Q, Aug 6, 2026latest filing that reports the weakness. Read it on SEC EDGAR
#360 of 1,250on the Clock by time open, tied with 18 other companies that share its start date. See the Clock

Still filing, and no annual report of its own says the weakness is fixed.

Checked against SEC EDGAR: Oct 29, 2026 · Entry #11474

Filings with a weakness21
First in our dataSep 13, 2021
AuditorPricewaterhouseCoopers LLP

Causes the company named

Segregation of duties · 21Financial close and reporting · 21Accounting expertise and resources · 21Entity-level and governance · 20ITGC: user access · 6ITGC: change management · 6ITGC: general · 6

What the latest filing says

Based on our evaluation, our chief executive officer and chief financial officer have concluded that our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were not effective as of June 30, 2026 because of the material weaknesses in our internal control over financial reporting described below. 26 Notwithstanding the material weaknesses, management believes the unaudited condensed consolidated financial statements included in Part I of this Quarterly Report present fairly, in all material respects, our financial condition, results of operations and cash flows as of and for the periods presented in accordance with generally accepted accounting principles in the United States. Material Weaknesses in Internal Control Over Financial Reporting In connection with the preparation of our consolidated financial statements for the year ended December 31, 2020, we identified material weaknesses in our internal control over financial reporting, two of which remain unremediated as of June 30, 2026. A material weakness is a deficien [...]

From the controls section of the 10-Q filed Aug 6, 2026. Read the full filing on SEC EDGAR.

Company response: Climb Bio, Inc. can send a statement or a link to its remediation update to russell@ctrlworx.com. We post it here, unedited and dated.

Filings

FiledFormPeriodControlsCausesFiling
Aug 6, 202610-QJun 30, 2026Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
May 7, 202610-QMar 31, 2026Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
Mar 5, 202610-KDec 31, 2025Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
Nov 6, 202510-QSep 30, 2025Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
Aug 12, 202510-QJun 30, 2025Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
May 14, 202510-QMar 31, 2025Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
Mar 25, 202510-KDec 31, 2024Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resourcesEDGAR
Nov 12, 202410-QSep 30, 2024Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
Aug 14, 202410-QJun 30, 2024Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
May 15, 202410-QMar 31, 2024Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
Mar 28, 202410-KDec 31, 2023Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
Nov 14, 202310-QSep 30, 2023Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
Aug 10, 202310-QJun 30, 2023Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
May 11, 202310-QMar 31, 2023Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
Mar 6, 202310-KDec 31, 2022Not effectiveSegregation of duties; Financial close and reporting; Accounting expertise and resources; Entity-level and governanceEDGAR
Nov 14, 202210-QSep 30, 2022Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; ITGC: user access; ITGC: change management; ITGC: general; Entity-level and governanceEDGAR
Aug 15, 202210-QJun 30, 2022Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; ITGC: user access; ITGC: change management; ITGC: general; Entity-level and governanceEDGAR
May 16, 202210-QMar 31, 2022Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; ITGC: user access; ITGC: change management; ITGC: general; Entity-level and governanceEDGAR
Mar 7, 202210-KDec 31, 2021Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; ITGC: user access; ITGC: change management; ITGC: general; Entity-level and governanceEDGAR
Nov 8, 202110-QSep 30, 2021Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; ITGC: user access; ITGC: change management; ITGC: general; Entity-level and governanceEDGAR
Sep 13, 202110-QJun 30, 2021Material weakness stated, no ICFR conclusionSegregation of duties; Financial close and reporting; Accounting expertise and resources; ITGC: user access; ITGC: change management; ITGC: general; Entity-level and governanceEDGAR

Others on the Clock in the same industry

By SEC industry code: 2834, Pharmaceutical Preparations, then related codes.

Follow CLYM for free

Get an email when Climb Bio, Inc files a 10-K or 10-Q that reports a material weakness, or says its controls are effective again.

Want the next one the day it's filed?

MW Pro sends an alert the day a company you follow reports a material weakness or says it fixed one. Founding price $990 a year.

Join the MW Pro waitlistLook up any company in Controls Radar™

Watch List Weekly: new material weaknesses, fixes and the longest-running cases, every Monday.

One email to confirm, then one email each Monday. Every email has a one-click unsubscribe. Privacy policy

Based on public SEC filings. Causes are grouped into standard categories by Ctrl Worx. The filings are the authority. Ctrl Worx is not affiliated with Climb Bio, Inc. or the SEC. Not investment advice. Why you can rely on the Watch List.